Previous Close | 22.62 |
Open | 22.72 |
Bid | 23.07 x 100 |
Ask | 23.17 x 300 |
Day's Range | 22.66 - 23.84 |
52 Week Range | 20.67 - 42.48 |
Volume | |
Avg. Volume | 1,282,214 |
Market Cap | 2.871B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.77 |
Earnings Date | May 09, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 55.38 |
PASADENA, Calif., April 29, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
PASADENA, Calif., April 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key
PASADENA, Calif., April 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024.